{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:39:04Z","timestamp":1768019944645,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05929-2","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:23:21Z","timestamp":1757424201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The multidrug resistance protein inhibitor, MK571 inhibits the hypercontractility state in prostate from obese mice"],"prefix":"10.1007","volume":"43","author":[{"given":"Gabriela Reolon","family":"Passos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natal\u00edcia","family":"de Jesus Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana G.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luiz","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Almeida","family":"Schenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Fregonesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-6677","authenticated-orcid":false,"given":"Fabiola Zakia","family":"M\u00f3nica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"4","key":"5929_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00345-008-0284-x","volume":"26","author":"AA Yassin","year":"2008","unstructured":"Yassin AA, El-Sakka AI, Saad F, Gooren LJ (2008) Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 26(4):359\u2013364. https:\/\/doi.org\/10.1007\/s00345-008-0284-xEpub 2008 Jul 2","journal-title":"World J Urol"},{"issue":"9","key":"5929_CR2","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","volume":"102","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z (2008) Extended-release Tolterodine with or without Tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU Int 102(9):1133\u20131139. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07761.x","journal-title":"BJU Int"},{"key":"5929_CR3","doi-asserted-by":"publisher","unstructured":"D\u2019Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, Hamid R, Homma Y, Marcelissen T, Rademakers K, Schizas A, Singla A, Soto I, Tse V, de Wachter S, Herschorn S, [2019]; Standardisation Steering Committee ICS and the ICS Working Group on Terminology for Male Lower Urinary Tract & pelvic floor symptoms and dysfunction. The international continence society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn 38(2):433\u2013477. https:\/\/doi.org\/10.1002\/nau.23897","DOI":"10.1002\/nau.23897"},{"issue":"6","key":"5929_CR4","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.juro.2011.07.067","volume":"186","author":"DF Penson","year":"2011","unstructured":"Penson DF, Munro HM, Signorello LB, Blot WJ, Fowke JH (2011) Urologic diseases in America project. Obesity, physical activity and lower urinary tract symptoms: results from the Southern community cohort study. J Urol 186(6):2316\u20132322. https:\/\/doi.org\/10.1016\/j.juro.2011.07.067","journal-title":"J Urol"},{"issue":"11","key":"5929_CR5","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00345-020-03106-1","volume":"38","author":"C De Nunzio","year":"2020","unstructured":"De Nunzio C, Salonia A, Gacci M, Ficarra V (2020) Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol 38(11):2771\u20132779. https:\/\/doi.org\/10.1007\/s00345-020-03106-1","journal-title":"World J Urol"},{"key":"5929_CR6","doi-asserted-by":"publisher","unstructured":"Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE (2020) Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 24;11(1):1987. https:\/\/doi.org\/10.1038\/s41467-020-15913-6","DOI":"10.1038\/s41467-020-15913-6"},{"key":"5929_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jnutbio.2017.12.009","volume":"55","author":"FB Calmasini","year":"2018","unstructured":"Calmasini FB, de Oliveira MG, Alexandre EC, Silva FH, Tavares EBG, Andr\u00e9 DM, Zapparoli A, Antunes E (2018) Obesity-induced mouse benign prostatic hyperplasia (BPH) is improved by treatment with resveratrol: implication of oxidative stress, insulin sensitivity and neuronal growth factor. J Nutr Biochem 55:53\u201358. https:\/\/doi.org\/10.1016\/j.jnutbio.2017.12.009","journal-title":"J Nutr Biochem"},{"key":"5929_CR8","doi-asserted-by":"publisher","first-page":"1145860","DOI":"10.3389\/fphar.2023.1145860","volume":"10","author":"GR Passos","year":"2023","unstructured":"Passos GR, de Oliveira MG, Ghezzi AC, Mello GC, Levi D, Ancona CA, Teixeira SA, Muscar\u00e1 MN, Grespan Bottoli CB, Vilela de Melo L, de Oliveira E, Antunes E, M\u00f3nica FZ (2023) Periprostatic adipose tissue (PPAT) supernatant from obese mice releases Anticontractile substances and increases human prostate epithelial cell proliferation: the role of nitric oxide and adenosine. Front Pharmacol 10:14:1145860. https:\/\/doi.org\/10.3389\/fphar.2023.1145860","journal-title":"Front Pharmacol"},{"issue":"1","key":"5929_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrurol.2017.181","volume":"15","author":"FZ M\u00f3nica","year":"2018","unstructured":"M\u00f3nica FZ, Antunes E (2018) Stimulators and activators of soluble guanylate cyclase for urogenital disorders. Nat Rev Urol 15(1):42\u201354. https:\/\/doi.org\/10.1038\/nrurol.2017.181","journal-title":"Nat Rev Urol"},{"issue":"9","key":"5929_CR10","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1161\/ATVBAHA.115.306133","volume":"35","author":"C Krawutschke","year":"2015","unstructured":"Krawutschke C, Koesling D, Russwurm M (2015) Cyclic GMP in vascular relaxation: export is of similar importance as degradation. Arterioscler Thromb Vasc Biol 35(9):2011\u20132019. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306133","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5929_CR11","doi-asserted-by":"publisher","unstructured":"Wolf R, Grammbauer S, Palankar R, Tolksdorf C, Moritz E, B\u00f6hm A, Hasan M, Hafkemeyer A, Greinacher A, Tzvetkov MV, Rauch BH, Jedlitschky G (2022) Specific inhibition of the transporter MRP4\/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets. Haematologica 107(9):2206\u20132217. https:\/\/doi.org\/10.3324\/haematol.2021.279761","DOI":"10.3324\/haematol.2021.279761"},{"key":"5929_CR12","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chen S, Luo L, Greenly S, Shi H, Xu JJ, Yan C (2023) Role of cAMP in Cardiomyocyte Viability: Beneficial or Detrimental? Circ Res 133(11):902\u2013923. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.322652","DOI":"10.1161\/CIRCRESAHA.123.322652"},{"key":"5929_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-981-13-7647-4_12","volume":"1141","author":"H Amawi","year":"2019","unstructured":"Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S (2019) ABC Transporter-Mediated Multidrug-Resistant cancer. Adv Exp Med Biol 1141:549\u2013580. https:\/\/doi.org\/10.1007\/978-981-13-7647-4_12","journal-title":"Adv Exp Med Biol"},{"key":"5929_CR14","doi-asserted-by":"publisher","unstructured":"Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 100(16):9244-9. https:\/\/doi.org\/10.1073\/pnas.1033060100. Epub 2003 Jun 30. PMID: 12835412; PMCID: PMC170903","DOI":"10.1073\/pnas.1033060100"},{"issue":"6","key":"5929_CR15","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1097\/01.ju.0000180411.03808.cb","volume":"174","author":"M Rius","year":"2005","unstructured":"Rius M, Thon WF, Keppler D, Nies AT (2005) Prostanoid transport by multidrug resistance protein 4 (MRP4\/ABCC4) localized in tissues of the human urogenital tract. J Urol 174(6):2409\u20132414. https:\/\/doi.org\/10.1097\/01.ju.0000180411.03808.cb","journal-title":"J Urol"},{"issue":"4","key":"5929_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41594-023-01176-4","volume":"31","author":"S Pourmal","year":"2024","unstructured":"Pourmal S, Green E, Bajaj R, Chemmama IE, Knudsen GM, Gupta M, Sali A, Cheng Y, Craik CS, Kroetz DL, Stroud RM (2024) Structural basis of prostaglandin efflux by MRP4. Nat Struct Mol Biol 31(4):621\u2013632. https:\/\/doi.org\/10.1038\/s41594-023-01176-4","journal-title":"Nat Struct Mol Biol"},{"key":"5929_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.phrs.2016.04.002","volume":"107","author":"T Belleville-Rolland","year":"2016","unstructured":"Belleville-Rolland T, Sassi Y, Decouture B, Dreano E, Hulot JS, Gaussem P, Bachelot-Loza C (2016) MRP4 (ABCC4) as a potential Pharmacologic target for cardiovascular disease. Pharmacol Res 107:381\u2013389. https:\/\/doi.org\/10.1016\/j.phrs.2016.04.002","journal-title":"Pharmacol Res"},{"issue":"11","key":"5929_CR18","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1111\/bph.15593","volume":"179","author":"RMH Grange","year":"2022","unstructured":"Grange RMH, Preedy MEJ, Renukanthan A, Dignam JP, Lowe VJ, Moyes AJ, P\u00e9rez-Ternero C, Aubdool AA, Baliga RS, Hobbs AJ (2022) Multidrug resistance proteins preferentially regulate natriuretic peptide-driven cGMP signalling in the heart and vasculature. Br J Pharmacol 179(11):2443\u20132459. https:\/\/doi.org\/10.1111\/bph.15593","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5929_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.118.250076","volume":"367","author":"GM Bertollotto","year":"2018","unstructured":"Bertollotto GM, de Oliveira MG, Alexandre EC, Calmasini FB, Passos GR, Antunes E, M\u00f3nica FZ (2018) Inhibition of multidrug resistance proteins by MK 571 enhances bladder, prostate, and urethra relaxation through cAMP or cGMP accumulation. J Pharmacol Exp Ther 367(1):138\u2013146. https:\/\/doi.org\/10.1124\/jpet.118.250076","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"5929_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jsxm.2017.02.005","volume":"14","author":"C Boydens","year":"2017","unstructured":"Boydens C, Pauwels B, Vanden Daele L, Van de Voorde J (2017) Inhibition of Cyclic GMP export by multidrug resistance protein 4: A new strategy to treat erectile dysfunction?? J Sex Med 14(4):502\u2013509. https:\/\/doi.org\/10.1016\/j.jsxm.2017.02.005","journal-title":"J Sex Med"},{"issue":"3","key":"5929_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/andr.13340","volume":"11","author":"MG de Oliveira","year":"2023","unstructured":"de Oliveira MG, Passos GR, de Gomes ET, Leonardi GR, Zapparoli A, Antunes E, M\u00f3nica FZ (2023) Inhibition of multidrug resistance proteins by MK571 restored the erectile function in obese mice through cGMP accumulation. Andrology 11(3):611\u2013620. https:\/\/doi.org\/10.1111\/andr.13340","journal-title":"Andrology"},{"issue":"4","key":"5929_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/S0002-9440(10)63513-4","volume":"163","author":"P Dazert","year":"2003","unstructured":"Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, B\u00f6hm M, Warzok R, Kerb R, Brinkmann U, Schaeffeler E, Schwab M, Cascorbi I, Jedlitschky G, Kroemer HK (2003) Expression and localization of the multidrug resistance protein 5 (MRP5\/ABCC5), a cellular export pump for Cyclic nucleotides, in human heart. Am J Pathol 163(4):1567\u20131577. https:\/\/doi.org\/10.1016\/S0002-9440(10)63513-4","journal-title":"Am J Pathol"},{"key":"5929_CR23","doi-asserted-by":"crossref","unstructured":"Nies AT, Spring H, Thon WF, Keppler D, Jedlitschky G (2002) Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J Urol 167(5):2271-5. PMID: 11956491","DOI":"10.1016\/S0022-5347(05)65141-5"},{"issue":"7","key":"5929_CR24","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1172\/JCI45023","volume":"121","author":"Y Hara","year":"2011","unstructured":"Hara Y, Sassi Y, Guibert C, Gambaryan N, Dorfm\u00fcller P, Eddahibi S, Lompr\u00e9 AM, Humbert M, Hulot JS (2011) Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest 121(7):2888\u20132897. https:\/\/doi.org\/10.1172\/JCI45023","journal-title":"J Clin Invest"},{"key":"5929_CR25","doi-asserted-by":"publisher","DOI":"10.1124\/mol.119.118927","author":"MC Michel","year":"2020","unstructured":"Michel MC, Murphy TJ, Motulsky HJ (2020) Mol Pharmacol 97(1):49\u201360. New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology https:\/\/doi.org\/10.1124\/mol.119.118927"},{"issue":"4","key":"5929_CR26","doi-asserted-by":"publisher","first-page":"e13851","DOI":"10.1111\/1440-1681.13851","volume":"51","author":"AC Ghezzi","year":"2024","unstructured":"Ghezzi AC, Passos GR, de Oliveira MG, Oliveira AL, Assis-Mendon\u00e7a GR, de Mello GC, Antunes E, Monica FZ (2024) A 2-week treatment with 5-azacytidine improved the hypercontractility state in prostate from obese mice: role of the nitric oxide-cyclic Guanosine monophosphate signalling pathway. Clin Exp Pharmacol Physiol R 51(4):e13851. https:\/\/doi.org\/10.1111\/1440-1681.13851","journal-title":"Clin Exp Pharmacol Physiol R"},{"issue":"6","key":"5929_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1023\/a:1012823120935","volume":"33","author":"M Dean","year":"2001","unstructured":"Dean M, Allikmets R (2001) Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33(6):475\u2013479. https:\/\/doi.org\/10.1023\/a:1012823120935","journal-title":"J Bioenerg Biomembr"},{"key":"5929_CR28","doi-asserted-by":"publisher","unstructured":"Deeley RG, Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett.13;580(4):1103-11. https:\/\/doi.org\/10.1016\/j.febslet.2005.12.036","DOI":"10.1016\/j.febslet.2005.12.036"},{"issue":"6","key":"5929_CR29","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1074\/jbc.M112.435925","volume":"288","author":"C Sinha","year":"2013","unstructured":"Sinha C, Ren A, Arora K, Moon CS, Yarlagadda S, Zhang W, Cheepala SB, Schuetz JD, Naren AP (2013) Multi-drug resistance protein 4 (MRP4)-mediated regulation of fibroblast cell migration reflects a dichotomous role of intracellular Cyclic nucleotides. J Biol Chem 288(6):3786\u20133794. https:\/\/doi.org\/10.1074\/jbc.M112.435925","journal-title":"J Biol Chem"},{"key":"5929_CR30","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.pestbp.2023.105543","volume":"195","author":"M Wu","year":"2023","unstructured":"Wu M, Zhang Y, Tian T, Xu D, Wu Q, Xie W, Zhang Y, Crickmore N, Guo Z, Wang S (2023) Assessment of the role of an ABCC transporter TuMRP1 in the toxicity of abamectin to Tetranychus urticae. Pestic Biochem Physiol 195:105543. https:\/\/doi.org\/10.1016\/j.pestbp.2023.105543","journal-title":"Pestic Biochem Physiol"},{"issue":"7","key":"5929_CR31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/nau.25242","volume":"42","author":"S Hu","year":"2023","unstructured":"Hu S, Huang R, Keller P, G\u00f6tz M, Tamalunas A, Weinhold P, Waidelich R, Stief CG, Hennenberg M (2023) Selective Inhibition of neurogenic, but not agonist-induced contractions by phospholipase A2 inhibitors points to presynaptic phospholipase A2 functions in contractile neurotransmission to human prostate smooth muscle. Neurourol Urodyn 42(7):1522\u20131531. https:\/\/doi.org\/10.1002\/nau.25242","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"5929_CR32","doi-asserted-by":"publisher","first-page":"e23028","DOI":"10.1096\/fj.202300561R","volume":"37","author":"H Choi","year":"2023","unstructured":"Choi H, Miller MR, Nguyen HN, Rohrbough JC, Koch SR, Boatwright N, Yarboro MT, Sah R, McDonald WH, Reese JJ, Stark RJ, Lamb FS (2023) LRRC8A anion channels modulate vascular reactivity via association with myosin phosphatase Rho interacting protein. FASEB J 37(7):e23028. https:\/\/doi.org\/10.1096\/fj.202300561R","journal-title":"FASEB J"},{"issue":"4","key":"5929_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/BF02220621","volume":"43","author":"M Depr\u00e9","year":"1992","unstructured":"Depr\u00e9 M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, De Schepper PJ (1992) Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man. Eur J Clin Pharmacol 43(4):427\u2013430. https:\/\/doi.org\/10.1007\/BF02220621","journal-title":"Eur J Clin Pharmacol"},{"key":"5929_CR34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00238.2023","author":"ET Gomes","year":"2024","unstructured":"Gomes ET, Passos GR, Antunes NJ, de Oliveira MG, de Souza VB, Schenka AA, da Costa JL, Antunes E, M\u00f3nica FZ (2024) The multidrug resistance protein (MRP) 4 is expressed and functionally active in isolated bladder from pig. Am J Physiol Regul Integr Comp Physiol. https:\/\/doi.org\/10.1152\/ajpregu.00238.2023","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"5929_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.bcp.2018.03.028","volume":"152","author":"CB Mendes-Silverio","year":"2018","unstructured":"Mendes-Silverio CB, Lescano CH, Zaminelli T, Sollon C, Anh\u00ea GF, Antunes E, M\u00f3nica FZ (2018) Activation of soluble Guanylyl cyclase with Inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy. Biochem Pharmacol 152:165\u2013173. https:\/\/doi.org\/10.1016\/j.bcp.2018.03.028","journal-title":"Biochem Pharmacol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05929-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05929-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:47Z","timestamp":1767996227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05929-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5929"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05929-2","relation":{"references":[{"id-type":"doi","id":"10.1124\/mol.119.118927","asserted-by":"subject"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"546"}}